https://doi.org/10.18502/ijrm.v13i11.7965
statistics
- 632 Abstract Views
- 268 PDF Views
- 0 HTML Views
authors
-
Niloofar Motaref
Niloofar Motaref
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
-
Sheyda Jouhari
Sheyda Jouhari
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
-
Afsaneh Mohammadzadeh
Afsaneh Mohammadzadeh
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
-
Somaieh Kazemnejad
Somaieh Kazemnejad
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
-
Narges Madadi
Narges Madadi
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
-
Sadaf Eghtedari
Sadaf Eghtedari
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
-
Abolfazl Ghoodjani
Abolfazl Ghoodjani
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Published Date
- Nov 22, 2020
Comparison of the effects of Duphaston and Cetrotide on oocyte and embryo quality in women undergoing ICSI: A cross-sectional study
Abstract
Background: Premature luteinizing hormone (LH) surge is one of the causes for assisted reproductive technology cycle cancellation, and it is needed to find novel approaches with improved efficacy and safety profile.
Objective: To compare the effects of Duphaston and Cetrotide on the prevention of premature LH surge and characteristics of retrieved follicles and embryos in women undergoing intracytoplasmic sperm injection.
Materials and Methods: In this retrospective cross-sectional study, 200 patients who were administrated recombinant follicle-stimulating hormone from the third day of menstruation cycle were included. When the follicular diameter reached above 13-14 mm, Cetrotide was prescribed in the control group, while in the case group, Duphaston was taken orally from the third day of cycle. The retrieved oocytes were fertilized in vitro by intracytoplasmic sperm. The level of hormones on the third day of menstruation and the characteristic of follicles, oocytes, and embryos were compared between the two groups.
Results: Duphaston successfully inhibits premature LH surge. There was no significant difference in the level of follicle-stimulating hormone, estradiol, and LH between the case and control groups (p > 0.05). However, results also showed that Duphaston causes more oocyte retrieval in comparison with Cetrotide (p = 0.04). Although, the number of follicles above 14 mm, mature oocyte, and the total number of viable embryos in the case group was slightly higher, it did not reach a significant difference compared with the control group (p > 0.05).
Conclusion: Duphaston could be used as an appropriate medication instead of gonadotropin-releasing hormone antagonists in women undergoing controlled ovarian hyperstimulation. Duphaston prescription not only prevents premature LH surge but also improves the number of retrieved oocytes.
Key words: Duphaston, Cetrorelix, Dydrogesterone, COH, GnRh antagonis.
References
[2] Hajipour H, Nejabati HR, Latifi Z, Hamdi K, Bahrami−asl Z, Fattahi A, et al. Lymphocytes immunotherapy for preserving pregnancy: mechanisms and Challenges. Am J Reprod Immunol 2018; 80: e12853.
[3] Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 2015; 104: 62–70. e3.
[4] Zhu X, Zhang X, Fu Y. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine 2015; 94: e909.
[5] Venetis CA, Kolibianakis EM, Papanikolaou E, Bontis J, Devroey P, Tarlatzis BC. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis. Hum Reprod Update 2007; 13: 343–355.
[6] Bosch E, Valencia I, Escudero E, Crespo J, Simón C, Remohí J, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 2003; 80: 1444–1449.
[7] Cédrin-Durnerin I, Bständig B, Parneix I, Bied- Damon V, Avril C, Decanter C, et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod 2007; 22: 109–116.
[8] Richter TA, Robinson JE, Evans NP. Progesterone blocks the estradiol-stimulated luteinizing hormone surge by disrupting activation in response to a stimulatory estradiol signal in the ewe. Biol Reprod 2002; 67: 119–125.
[9] Zhu X, Ye H, Fu Y. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertil Steril 2017; 108: 505–512.
[10] Eftekhar M, Hoseini M, Saeed L. Progesteroneprimed ovarian stimulation in polycystic ovarian syndrome: An RCT. Int J Reprod BioMed 2019; 17: 671–676.
[11] Saharkhiz N, Zamaniyan M, Salehpour S, Zadehmodarres S, Hoseini S, Cheraghi L, et al. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles. Gynecol Endocrinol 2016; 32: 213–217.
[12] Fitzpatrick LA, Good A. Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril 1999; 72: 389–397.
[13] Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril 2011; 95: 1961–1965.
[14] Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas 2003; 46 (Suppl.): S7–S16.
[15] Kato O, Kawasaki N, Bodri D, Kuroda T, Kawachiya S, Kato K, et al. Neonatal outcome and birth defects in 6623 singletons born following minimal ovarian stimulation and vitrified versus fresh single embryo transfer. Eur J Obstet Gynecol Reprod Biol 2012; 161: 46–50.
[16] Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 2018; 33: 229–237.
[17] Zavareh S, Saberivand A, Salehnia M. The effect of progesterone on the in vitro maturation and developmental competence of mouse germinal vesicle oocytes. Int J Fertil Steril 2009; 3: 21–28.
[18] Hamdi K, Farzadi L, Ghasemzadeh A, Navali N, Atashkhoei S, Pia H, et al. Comparison of medroxyprogesterone acetate with cetrotide for prevention of premature luteinizing hormone surges in women undergoing in vitro fertilization. Int J Women’s Heal Reprod Sci 2018; 6: 187–191.
[19] Richter TA, Robinson JE, Lozano JM, Evans NP. Progesterone can block the preovulatory gonadotropin−releasing hormone/luteinising hormone surge in the ewe by a direct inhibitory action on oestradiol−responsive cells within the hypothalamus. J Neuroendocrinol 2005; 17: 161–169.
[20] Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab 1984; 58: 378–383.
[21] Harris TG, Dye S, Robinson JE, Skinner DC, Evans NP. Progesterone can block transmission of the estradiol-induced signal for luteinizing hormone surge generation during a specific period of time immediately after activation of the gonadotropinreleasing hormone surge-generating system. Endocrinology 1999; 140: 827–834.